Ilmarinen Mutual Pension Insurance Co Has $28.54 Million Position in Amgen Inc. $AMGN

Key Points

• Ilmarinen Mutual Pension Insurance Co trimmed its Amgen stake by 7.2% in the fourth quarter, but still held 87,200 shares worth about $28.54 million.
• Amgen reported better-than-expected quarterly results, posting EPS of $5.15 versus $4.77 expected and revenue of $8.62 billion, while raising its FY 2026 EPS guidance to 21.7 to 23.1.
• The company also announced a quarterly dividend of $2.52 per share, equal to an annualized yield of about 3.0%, while analysts currently have an overall Hold rating and an average target price of $355.19.

Ilmarinen Mutual Pension Insurance Co reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 87,200 shares of the medical research company's stock after selling 6,800 shares during the period. Ilmarinen Mutual Pension Insurance Co's holdings in Amgen were worth $28,541,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. High Note Wealth LLC grew its holdings in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company's stock worth $166,000 after acquiring an additional 28 shares during the period. West Family Investments Inc. grew its holdings in Amgen by 1.1% during the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company's stock worth $779,000 after acquiring an additional 30 shares during the period. Viawealth LLC grew its holdings in Amgen by 0.4% during the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company's stock worth $2,023,000 after acquiring an additional 30 shares during the period. LOM Asset Management Ltd grew its holdings in Amgen by 1.2% during the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company's stock worth $721,000 after acquiring an additional 30 shares during the period. Finally, Smith Salley Wealth Management grew its holdings in Amgen by 0.3% during the 4th quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company's stock worth $3,530,000 after acquiring an additional 30 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Guggenheim decreased their price target on Amgen from $351.00 to $340.00 and set a "neutral" rating for the company in a report on Monday, May 4th. TD Cowen reissued a "buy" rating on shares of Amgen in a research report on Wednesday, February 4th. Truist Financial increased their price objective on shares of Amgen from $325.00 to $327.00 and gave the stock a "hold" rating in a research report on Friday, May 1st. Daiwa Securities Group cut their price objective on shares of Amgen from $410.00 to $390.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 13th. Finally, Argus cut their price objective on shares of Amgen from $400.00 to $375.00 and set a "buy" rating on the stock in a research report on Wednesday, May 20th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $355.19.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $336.48 on Friday. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The stock has a market cap of $181.60 billion, a price-to-earnings ratio of 23.42, a PEG ratio of 3.37 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The firm's 50-day simple moving average is $342.83 and its 200 day simple moving average is $345.39.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. Amgen's payout ratio is 70.15%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.85% of the company's stock.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.